focus -WSS

focus

author：leisure time 2025-09-06 04:38:06 - browse：774

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Just how do doctors, lawmakers, and the public define abortion?

hotspot

entertainment

WSS

Just how do doctors, lawmakers, and the public define abortion?

Anavex keeps shifting the goalposts in its clinical trials

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

First medicine developed to treat MASH expected to be approved soon

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

knowledge

focus

explore

Drug repurposing or repositioning? The language matters

Change Healthcare cyberattack prompts Medicare loan program

New air purifier tech could be key to improving indoor air quality

Naloxone nonprofit donates 200,000 doses after FDA approval

Dobbs anniversary: the lost opportunity of abortion as health care

In same hospitals, Black patients receive fewer opioids than white patients

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Headspace, Meta partner to launch VR meditation app for Quest

Affirmative action in medical school literally saved lives

Why failed clinical trials don’t always spell doom for a new drug

explore

What to know about Virgin Galactic's 1st mission taking paying customers to space

The drug industry has found itself all alone in Washington

South Korea throws huge K

What to know about Virgin Galactic's 1st mission taking paying customers to space

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

In same hospitals, Black patients receive fewer opioids than white patients

knowledge

hotspot

entertainment

Wikipedia